• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Avinger Inc.

    1/23/25 4:21:48 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001254850
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Avinger Inc
    SEC File Number
    001-36817
    Address of Issuer
    400 CHESAPEAKE DRIVE
    REDWOOD CITY
    CALIFORNIA
    94063
    Phone
    650-363-2400
    Name of Person for Whose Account the Securities are To Be Sold
    SOINSKI JEFFREY M
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    36902054.22319679101/23/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common01/21/2025Restricted Stock VestingIssuerCheckbox not checked369001/21/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    01/23/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jeffrey M. Soinski

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AVGR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVGR

    DatePrice TargetRatingAnalyst
    11/15/2021$2.50 → $2.00Buy
    Aegis Capital
    6/29/2021$2.50Buy
    B. Riley Securities
    More analyst ratings

    $AVGR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.

      SCHEDULE 13G/A - Avinger Inc (0001506928) (Subject)

      2/14/25 5:07:21 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avinger Inc (0001506928) (Filer)

      2/10/25 5:01:26 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Avinger Inc (0001506928) (Filer)

      2/5/25 5:00:31 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on Avinger with a new price target

      Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously

      11/15/21 12:33:44 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Avinger with a new price target

      B. Riley Securities initiated coverage of Avinger with a rating of Buy and set a new price target of $2.50

      6/29/21 6:16:21 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avinger Reports Third Quarter 2024 Results

      Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

      11/7/24 4:05:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

      REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

      10/29/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

      REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the

      10/24/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Vice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:35:20 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:34:44 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:34:02 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avinger Inc.

      SC 13G - Avinger Inc (0001506928) (Subject)

      11/14/24 3:23:30 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avinger Inc.

      SC 13G/A - Avinger Inc (0001506928) (Subject)

      11/13/24 11:13:40 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avinger Inc.

      SC 13G - Avinger Inc (0001506928) (Subject)

      6/21/24 4:45:23 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

      REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo

      8/5/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Avinger Announces Annual Meeting Results

      REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl

      12/23/20 4:50:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Financials

    Live finance-specific insights

    See more
    • Avinger Reports Third Quarter 2024 Results

      Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

      11/7/24 4:05:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

      REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

      10/29/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Second Quarter 2024 Results on August 8, 2024

      REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A

      7/29/24 8:45:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care